FDA Brief

Warning letters Drugs

FDA warning letter to

GTP International Corp

MediumIssued Aug 4, 2023Posted Aug 8, 2023Center for Drug Evaluation and Research | CDER

GTP International, a Mesquite, TX maker of OTC hand sanitizer, refused FDA's repeated requests for manufacturing records.

What happened

FDA sent a request for records about its drug manufacturing to the email address in GTP International's registration file on August 16, 2022, and sent it again on August 31, 2022. FDA also left a phone message on October 24, 2022, and sent a certified return-receipt letter that was delivered on November 22, 2022; none were answered. On August 1, 2023, the firm's president agreed by phone to respond by August 2, 2023, but did not, and FDA said it therefore has no indication of the level of quality assurance for drugs made at the facility.

What FDA found

  1. The company refused to let FDA see or copy records that FDA is allowed to demand from a registered drug manufacturer.

    FD&C Act section 301(e) (21 U.S.C. 331(e)); records request under section 704(a)(4) (21 U.S.C. 374(a)(4))
  2. The company did not answer FDA's records requests sent by email, phone and certified mail over roughly a year, so FDA could not judge the quality of the drugs it makes.

    FD&C Act section 704(a)(4) (21 U.S.C. 374(a)(4))

What FDA wants

FDA tells the company to reply within 48 hours to confirm or update its drug registration and listing status and to say whether it will provide the requested records. If it no longer makes drugs, it must delist all its drugs using the last lot expiration date as the marketing end date and deregister the facility.

Who should pay attention

  • brands and distributors that buy hand sanitizer from small OTC contract manufacturers
  • OTC drug makers that must answer FDA records requests under section 704(a)(4)
  • regulatory staff tracking hand sanitizer firms on FDA's do-not-use list

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Zenzi Pharmaceutical Industries Pvt. Ltd.

    Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.

    High risk
  3. Gulf States International, Inc.

    Gulf States International refused FDA requests for OTC drug manufacturing records, FDA says.

    Medium
  4. Zhao Qing Longda Biotechnology Co. Ltd.

    FDA says Zhao Qing Longda Biotechnology refused records access for OTC drugs, including children’s toothpaste, and placed its drugs on import alert.

    High risk